FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890844794> ?p ?o ?g. }

• W2890844794 endingPage "e0203878" @default.
• W2890844794 startingPage "e0203878" @default.
• W2890844794 abstract "Proton pump inhibitor use is associated with incident chronic kidney disease, chronic kidney disease progression and end-stage renal disease. However, the extent of proton pump inhibitor prescriptions to chronic kidney disease patients is still unclear.In a retrospective study, we enrolled patients (>18 years old) who received proton pump inhibitor in the out-patient setting from 2014 through 2015. All data was obtained from electronical medical records of Soonchunhyang Medical Center. The prescription patterns and characteristics of proton pump inhibitors were analyzed according to individual estimated glomerular filtration rate of the patients.During the study period 178,228 patients visited the out-patient clinic. Proton pump inhibitors were prescribed to 9,109 (5.11%) patients. In our sample, 50% were females and 9.8% were chronic kidney disease (eGFR<60mL/min/1.73 m2) patients. Among the patients with chronic kidney disease, 730 (8.0%) were categorized as stage 3 or 4 and 166 (1.8%) were categorized as stage 5 or end-stage renal disease. The prevalence of proton pump inhibitors prescription among chronic kidney disease patients was higher than in the non-chronic kidney disease group (p<0.001). Median duration of usage was 120 [interquartile range 63-273] days in the stage 3-4 group, 106 [56-266] days in the stage 5-end-stage renal disease group and 90 [56-176] days in the non-chronic kidney disease group. Patients in stage 3-4 group were prescribed longer duration of proton pump inhibitors than the non-chronic kidney disease group even after adjusting for age and sex (p<0.001). The main departments of medicine which prescribed proton pump inhibitors for the stage 3-4 group were gastroenterology (40.0%), cardiology (29.6%), nephrology (9.5%) and neurology (4.8%). Compared to the non-chronic kidney disease group, the stage 3-4 and stage 5-end-stage renal disease group were taking larger number of drugs simultaneously (6.90±4.17 vs4.54±2.43; p<0.001, 5.64±2.87 vs 4.54±2.34; p<0.001, respectively).Chronic kidney disease patients are taking proton pump inhibitors for a much longer duration compared to non-chronic kidney disease patients. Physicians should pay careful attention when prescribing proton pump inhibitors to high risk groups." @default.
• W2890844794 created "2018-09-27" @default.
• W2890844794 creator A5025168962 @default.
• W2890844794 creator A5036109427 @default.
• W2890844794 creator A5048790743 @default.
• W2890844794 creator A5050814795 @default.
• W2890844794 creator A5051385056 @default.
• W2890844794 creator A5057287330 @default.
• W2890844794 creator A5085158699 @default.
• W2890844794 creator A5086714791 @default.
• W2890844794 creator A5089750701 @default.
• W2890844794 date "2018-09-13" @default.
• W2890844794 modified "2023-10-10" @default.
• W2890844794 title "Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients" @default.
• W2890844794 cites W1796193177 @default.
• W2890844794 cites W1899351694 @default.
• W2890844794 cites W1957588549 @default.
• W2890844794 cites W1968895531 @default.
• W2890844794 cites W1971705529 @default.
• W2890844794 cites W1997052574 @default.
• W2890844794 cites W1997184163 @default.
• W2890844794 cites W2000296226 @default.
• W2890844794 cites W2030207051 @default.
• W2890844794 cites W2071398613 @default.
• W2890844794 cites W2090180612 @default.
• W2890844794 cites W2133637040 @default.
• W2890844794 cites W2155965977 @default.
• W2890844794 cites W2168546056 @default.
• W2890844794 cites W2227754270 @default.
• W2890844794 cites W2281035315 @default.
• W2890844794 cites W2335909636 @default.
• W2890844794 cites W2341772582 @default.
• W2890844794 cites W2587375020 @default.
• W2890844794 cites W2591563250 @default.
• W2890844794 cites W2607031541 @default.
• W2890844794 cites W2724110517 @default.
• W2890844794 cites W2794742922 @default.
• W2890844794 cites W95781732 @default.
• W2890844794 doi "https://doi.org/10.1371/journal.pone.0203878" @default.
• W2890844794 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6231691" @default.
• W2890844794 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30419006" @default.
• W2890844794 hasPublicationYear "2018" @default.
• W2890844794 type Work @default.
• W2890844794 sameAs 2890844794 @default.
• W2890844794 citedByCount "17" @default.
• W2890844794 countsByYear W28908447942018 @default.
• W2890844794 countsByYear W28908447942019 @default.
• W2890844794 countsByYear W28908447942020 @default.
• W2890844794 countsByYear W28908447942021 @default.
• W2890844794 countsByYear W28908447942022 @default.
• W2890844794 countsByYear W28908447942023 @default.
• W2890844794 crossrefType "journal-article" @default.
• W2890844794 hasAuthorship W2890844794A5025168962 @default.
• W2890844794 hasAuthorship W2890844794A5036109427 @default.
• W2890844794 hasAuthorship W2890844794A5048790743 @default.
• W2890844794 hasAuthorship W2890844794A5050814795 @default.
• W2890844794 hasAuthorship W2890844794A5051385056 @default.
• W2890844794 hasAuthorship W2890844794A5057287330 @default.
• W2890844794 hasAuthorship W2890844794A5085158699 @default.
• W2890844794 hasAuthorship W2890844794A5086714791 @default.
• W2890844794 hasAuthorship W2890844794A5089750701 @default.
• W2890844794 hasBestOaLocation W28908447941 @default.
• W2890844794 hasConcept C119060515 @default.
• W2890844794 hasConcept C126322002 @default.
• W2890844794 hasConcept C159641895 @default.
• W2890844794 hasConcept C2426938 @default.
• W2890844794 hasConcept C2778653478 @default.
• W2890844794 hasConcept C2780091579 @default.
• W2890844794 hasConcept C2781025758 @default.
• W2890844794 hasConcept C71924100 @default.
• W2890844794 hasConcept C90924648 @default.
• W2890844794 hasConcept C98274493 @default.
• W2890844794 hasConceptScore W2890844794C119060515 @default.
• W2890844794 hasConceptScore W2890844794C126322002 @default.
• W2890844794 hasConceptScore W2890844794C159641895 @default.
• W2890844794 hasConceptScore W2890844794C2426938 @default.
• W2890844794 hasConceptScore W2890844794C2778653478 @default.
• W2890844794 hasConceptScore W2890844794C2780091579 @default.
• W2890844794 hasConceptScore W2890844794C2781025758 @default.
• W2890844794 hasConceptScore W2890844794C71924100 @default.
• W2890844794 hasConceptScore W2890844794C90924648 @default.
• W2890844794 hasConceptScore W2890844794C98274493 @default.
• W2890844794 hasFunder F4320321301 @default.
• W2890844794 hasIssue "9" @default.
• W2890844794 hasLocation W28908447941 @default.
• W2890844794 hasLocation W28908447942 @default.
• W2890844794 hasLocation W28908447943 @default.
• W2890844794 hasLocation W28908447944 @default.
• W2890844794 hasOpenAccess W2890844794 @default.
• W2890844794 hasPrimaryLocation W28908447941 @default.
• W2890844794 hasRelatedWork W1989851633 @default.
• W2890844794 hasRelatedWork W1989919608 @default.
• W2890844794 hasRelatedWork W2097177561 @default.
• W2890844794 hasRelatedWork W2146750823 @default.
• W2890844794 hasRelatedWork W3129939113 @default.
• W2890844794 hasRelatedWork W3154836626 @default.
• W2890844794 hasRelatedWork W4200612770 @default.
• W2890844794 hasRelatedWork W4213247523 @default.

• next